Delpharm Development Leiden

Delpharm Development Leiden is a specialized Contract Development and Manufacturing Organization (CDMO) based in the Netherlands, focusing on the development of complex injectable drug products. The facility, which was acquired from Dr. Reddy's Laboratories in 2023, has a long-standing expertise in advanced drug delivery systems such as liposomes, microspheres, and sustained-release formulations. It provides a comprehensive suite of services including formulation development, analytical chemistry, and GMP manufacturing for clinical trials. As part of the broader Delpharm network, the Leiden site serves global pharmaceutical and biotech clients seeking specialized expertise in difficult-to-formulate therapeutics.